The potential usefulness of a BCL6 inhibitor for some types of malignant and autoimmune disease has led several groups to develop approaches to perturb the cellular function of BCL6 with the ultimate aim of producing novel therapeutic agents. This evidence concerns the gene BCL6 and autoimmune disease.